Global Tumor Ablation Market Share, Size, Trends, Industry Analysis Report: By Technology (Radiofrequency (RF) Ablation, Microwave Ablation, Cryoablation, Others); By Mode of Treatment; By Application and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2024 - 2032
- Published Date:Feb-2024
- Pages: 116
- Format: PDF
- Report ID: PM1214
- Base Year: 2023
- Historical Data: 2019-2022
Report Outlook
Global Tumor Ablation Market Size was valued at USD 1.60 billion in 2023. The tumor ablation industry is projected to grow from USD 1.78 billion in 2024 to USD 4.17 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.3% during the forecast period (2024 - 2032).
The incidence of cancer is rising due to factors such as aging populations, environmental pollution, smoking, and shifting lifestyles. These trends highlight the urgent need for effective treatments like tumor ablation driving the tumor ablation market revenue. Medical device companies and healthcare organizations are investing heavily in research and development to advance ablation technologies. For instance, in Nov 2022, Baird Medical secures FDA clearance for its microwave ablation system, expanding treatment options for thyroid nodules and other soft tissue diseases in the US. These innovations are driving market growth by offering more sophisticated and precise techniques for treating various types of cancers.
To Understand More About this Research: Request a Free Sample Report
Tumor ablation procedures represent minimally invasive alternatives to traditional surgery for treating solid tumors. There is a growing demand for targeted treatments capable of specifically locating and destroying tumors with rising cancer patients. Increased awareness and improved screening programs facilitate earlier cancer detection, enabling timely intervention with ablation techniques. These factors collectively drive market expansion, as medical advancements continue to enhance the efficacy and accessibility of tumor ablation therapies.
Tumor Ablation Market Trends:
The Rising Prevalence of Cancer Patients Are Driving the Market Growth
The rising prevalence of cancer patients increased the demand for tumor ablation procedures. These techniques, including radiofrequency, microwave, cryoablation, and laser ablation, provide targeted destruction of cancerous cells while sparing healthy tissue. They offer reduce trauma, less postoperative pain, quicker recovery times, and lower risks of complications compared to conventional open surgeries. Tumor ablation is becoming increasingly vital for managing solid tumors, especially early-stage tumors, as patient preference for minimally invasive treatments.
For instance, according to the Cancer Australia Statistics for the year 2022, Australia witnessed the diagnosis of 162,163 new cases of cancer, with 88,982 affecting males and 73,181 affecting females. The raising prevalence for cancer patient is driving demand in tumor ablation market share.
Increasing Patients and Surgeons’ Inclination Towards Minimally Invasive Procedures Will Drive the Growth of Market
The increasing leaning of patients and surgeons towards minimally invasive procedures will facilitate the growth of the tumor ablation market. Minimally invasive procedures, as compared to conventional open surgical procedures, need fewer incisions or needle insertion. As a result, there is less tissue damage, less blood loss, and a lower risk of complications. These procedures are typically associated with shorter hospital stays and quicker recovery times.
Advanced imaging technologies are frequently used in minimally invasive techniques, allowing surgeons to monitor and accurately target tumors. This enhances accuracy while also preserving healthy surrounding tissues. The surgical instruments are designed to give surgeons additional mobility and agility, allowing them to execute complicated surgeries with greater control and precision compared to open surgeries. The procedures use fewer incisions, lowering the risk of post-operative infections and thereby boosting demand for tumor ablations.
For instance, in January 2024The University of Chicago Medicine was the first health system in Illinois are utilizing histotripsy, a noninvasive technique that uses focused ultrasound energy for targeted destruction of liver tumors.
Tumor ablation Market Segment Insights:
Tumor ablation technology Insights:
The global tumor ablation market segmentation, based on technology includes radiofrequency (RF) ablation, microwave ablation, cryoablation, others. In 2023, the radiofrequency ablation segment accounted for the largest revenue share due to its efficiency and specificity in solid tumor ablation techniques in the liver and kidney. Radiofrequency ablation is used to treat multiple tumors simultaneously by using multiple electrodes placed at various sites, which enhances procedural efficiency. This advancement is expected to lead to increased adoption of evolved tumor ablation techniques.
The launch of radiofrequency ablation (RFA) had a deep impact on the tumor ablation market, resulting in a growing demand and expanded market share. For instance, in November 2020, Abbott launched the IonicRF Generator, approved by the U.S. Food and Drug Administration. This device provides a non-surgical, minimally invasive treatment for managing pain in the nervous system. The IonicRF Generator is a radiofrequency ablation device that uses heat to target specific nerves and block pain signals from reaching the brain.
Tumor ablation Application Insights:
The global tumor ablation market segmentation, based on application, includes liver cancer, lung cancer, kidney cancer, bone metastasis, others. The lung cancer emerged as the fastest-growing market segment in the forecast period. Cigarette smoking is the most significant contributor to lung cancer, responsible for the majority of cases. The carcinogens found in tobacco smoke cause damage to lung cells, gradually leading to the development of cancer. Smoking accounts for 80% of lung cancer-related deaths, while individuals who have never smoked make up the remaining 20% of lung cancer fatalities. The second major risk factor for lung cancer is exposure to radon gas. Additionally, air pollution, including fine particulate matter (PM2.5) and other pollutants originating from industrial activities, vehicles, and the combustion of fossil fuels, has been linked to an elevated risk of developing lung cancer.
For Instance, according to the Lung Cancer Research Foundation, in 2023, an estimated 238,340 people in the U.S. were diagnosed with lung cancer. The increasing incidence of lung cancer has initiated the utilization of tumor ablation procedures, significantly driving the tumor ablation market share.
Global Tumor Ablation Market, Segmental Coverage, 2019 - 2032 (USD Billion)
Source: Secondary Research, Primary Research, PMR Database and Analyst Review
Tumor ablation Regional Insights:
By region, the study provides the market insights into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. The North America tumor ablation market area is accounted to be the largest market in 2023. In North America, governments are investing in healthcare infrastructure, funding advanced medical technologies, and expediting regulatory approvals for innovative treatments, which improves the overall quality of cancer care.
For instance, in June 2023, the Biden-Harris Administration has allocated $50 million to the Persistent Poverty Initiative, aimed at mitigating the compounding impacts of persistent poverty on cancer outcomes. This initiative focuses on enhancing research capabilities, cultivating cancer prevention research, and championing the adoption of community-based programs. Notably, the Persistent Poverty Initiative marks the inaugural large-scale effort to tackle the structural and institutional elements of persistent poverty within the framework of cancer. The increasing government policies in cancer care treatment initiate the utilization of tumor ablation procedures, significantly driving the tumor ablation market share.
U.S tumor ablation market is expected to grow substantially during the anticipated years due to robust healthcare system with medical facilities and highly skilled healthcare providers. Across the country, major medical centers and hospitals provide specialized oncology services, such as tumor ablation, ensuring broad availability of these advanced treatments. The launch of a new product in the healthcare sector, particularly in advanced technologies like tumor ablation, reshapes the market landscape significantly. It introduces innovative features and capabilities that enhance treatment precision, efficacy, and patient outcomes. For instance, Bioventus Inc. launched the neXus SonaStar Elite handpiece with FDA approval. The handpiece is part of the neXus Ultrasonic Surgical Aspirator System, offering enhanced versatility and control through a proprietary digital algorithm. The system can operate at multiple frequencies, including the newly approved 36 kHz SonaStar Elite Handpiece. This groundbreaking technological innovation has contributed to the expansion of the tumor ablation market.
GLOBAL TUMOR ABLATION MARKET, REGIONAL COVERAGE, 2019 - 2032 (USD Billion)
Source: Secondary Research, Primary Research, PMR Database and Analyst Review
Asia Pacific tumor ablation market is expected to grow at fastest CAGR during the forecast period due to the increasing need for minimally invasive tumor ablation techniques and the safe therapeutic choices drive the growth of the market.
Asia Pacific industries are at the forefront of adopting automation and smart manufacturing technologies. Automated tumor ablations enhance productivity, reduce labor costs, and improve packaging accuracy, making them an attractive investment for manufacturers seeking to modernize their operations. Leveraging advanced automation technologies and artificial intelligence enhance machine performance, offering features like predictive maintenance, fault detection, and operational efficiency driving the market growth.
Furthermore, the increasing number of cancer patients led to the growth of the tumor ablation market. For instance, in August 2023, according to Union for International Cancer, in 2020, Asia accounted for 45% of the 2.3 million global breast cancer cases and more than half of the cervical cancer cases. Moreover, breast cancer mortality rates are increasing in all countries in the region, with a projected rise of nearly 20% by 2025 compared to 2020, especially in countries such as Indonesia and the Philippines.
India tumor ablation market is expected to grow substantially during the anticipated years due to increasingly healthcare providers and the general population becoming aware of the benefits of early cancer detection and advanced treatment options. Education campaigns and initiatives by healthcare organizations and governments are helping to raise awareness about the availability and effectiveness of tumor ablation as a minimally invasive treatment option. This rising awareness for availability and effectiveness for tumor ablation is boosting the market industry outlook.
Tumor Ablation Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the tumor ablation market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, tumor ablation industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global tumor ablation industry to benefit clients and increase the market sector. In recent years, the tumor ablation industry has offered some technological advancements. Major players in the tumor ablation market, including AngioDynamics Inc., Boston Scientific Corp., BVM Medical Ltd., BTG International Ltd., EDAP TMS S.A., Integra LifeSciences Holdings Corp., Medtronic plc., Mermaid Medical, SonaCare Medical LLC, St. Jude Medical Inc.
Boston Scientific Corporation is a global leader in manufacturing, developing, and distributing medical devices for use in a wide range of interventional medical specialties. The company is organized into two segments, Cardiovascular and MedSurg. In January 2024, Boston Scientific Corporation received approval from the U.S. Food and Drug Administration for the FARAPULSE Pulsed Field Ablation (PFA) System. This system is designed to isolate pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic paroxysmal atrial fibrillation (AF). It offers a novel alternative to the standard-of-care thermal ablation treatment.
Medtronic plc manufactures, develops, and sells device-based medical therapies to , physicians, clinicians, patients worldwide and healthcare systems. In December 2022, Medtronic plc has obtained clearance from the U.S. Food and Drug Administration for its OsteoCool 2.0 bone tumor ablation system. This advanced technology is designed for the treatment of painful bone metastases and benign bone tumors such as osteoid osteoma.
Key Companies in the Tumor Ablation Market Include:
- AngioDynamics Inc.
- Boston Scientific Corp.
- BVM Medical Ltd.
- BTG International Ltd.
- EDAP TMS S.A.
- Integra LifeSciences Holdings Corp.
- Medtronic plc.
- Mermaid Medical
- SonaCare Medical LLC
- St. Jude Medical Inc.
Tumor Ablation Industry Developments
- In April 2023, Compal Electronics has launched a radiofrequency ablation (RFA) system designed for percutaneous and intraoperative coagulation, along with soft tissue ablation. Also, the company has introduced a bilevel ventilator specifically designed for managing chronic obstructive pulmonary disease (COPD) and respiratory insufficiency resulting from central and/or mixed apneas.
- In March 2023, AngioDynamics has partnered with Minimax Medical to facilitate the global distribution of its array of products. The partnership contains the international distribution of Minimax Medical's advanced Radiofrequency Ablation System, specifically designed for treating tumors and nodules.
- In Feb 2024, AngioDynamics and Immunophotonics have recently announced a collaborative partnership to investigate the potential of combining immunotherapy with ablation techniques for the treatment of solid tumor cancers. This partnership integrates the use of Immunophotonics’ IP-001 with AngioDynamics’ ablation devices to explore the synergistic effects of ablation and immunotherapy.
Tumor Ablation Market Segmentation:
Tumor Ablation Technology Outlook
- Radiofrequency (RF) Ablation
- Microwave Ablation
- Cryoablation
- Others
Tumor Ablation Mode of Treatment Outlook
- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
Tumor Ablation Application Outlook
- Liver Cancer
- Lung Cancer
- Kidney Cancer
- Bone Metastasis
- Others
Tumor ablation Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia-Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Tumor ablation Report Scope:
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 1.60 billion |
|
Market size value in 2024 |
USD 1.78 billion |
|
Revenue Forecast in 2032 |
USD 4.17 billion |
|
CAGR |
11.3% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments covered |
|
|
Regional scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, region, and segmentation. |
FAQ's
The key companies in Tumor Ablation Market areAngioDynamics Inc., Boston Scientific Corp., BVM Medical Ltd., BTG International Ltd.,
The Tumor Ablation Market expected to grow at a CAGR of 11.3% during the forecast period.
Tumor Ablation Market report covering key segments are technology, mode of treatment, application and region.
North America is leading the global market
The key driving factors in Tumor Ablation Market Increasing prevalence of cancer worldwide will facilitate the growth of the market
The lung cancer has the fastest share in the global market
© 2024 Polaris Market Research and Consulting. All rights reserved
